FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 323:86-90 July 12, 1990 Number 2 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. Erythrocytosis occurs in 10 to 15 percent of renal-transplant recipients, and there is in vitro evidence that the production of erythropoietin is modulated by adenosine. METHODS. We prospectively evaluated the effects of theophylline, a nonselective adenosine antagonist, in eight patients with erythrocytosis after renal transplantation and in five normal controls. RESULTS. After an eight-week course of theophylline treatment, the mean (+/- SEM) serum erythropoietin levels were significantly reduced in both the renal-transplant recipients (from 60 +/- 14 units per liter at base line to 9 +/- 7 units after treatment; P less than 0.05) and the normal subjects (from 6.9 +/- 0.8 units per liter at base line to 4.7 +/- 0.5 units per liter after treatment; P less than 0.05). Similarly, the hematocrits were reduced in both the transplant recipients (from 0.58 +/- 0.04 at base line to 0.46 +/- 0.03 after treatment; P less than 0.05) and the normal subjects (from 0.43 +/- 0.01 at base line to 0.39 +/- 0.01; P less than 0.05). In the renal-transplant recipients, red-cell mass was also reduced after eight weeks of theophylline (from 3197 +/- 82 ml at base line to 2273 +/- 69 ml after treatment; P less than 0.05). The previous requirement of weekly phlebotomy was eliminated in all recipients. Plasma and urinary cyclic AMP levels were not increased. These effects were reproducible when the subjects were rechallenged with theophylline after a recovery period. CONCLUSIONS. Theophylline attenuates the production of erythropoietin in both normal subjects and patients with erythrocytosis after renal transplantation and may be useful in the treatment of the latter condition.

Source Information

Department of Medicine, Ochsner Medical Institutions, New Orleans, LA.

This article has been cited by other articles:

• Grenz, A., Zhang, H., Weingart, J., von Wietersheim, S., Eckle, T., Schnermann, J., Kohle, C., Kloor, D., Gleiter, C. H., Vallon, V., Eltzschig, H. K., Osswald, H. (2007). Lack of effect of extracellular adenosine generation and signaling on renal erythropoietin secretion during hypoxia. Am. J. Physiol. Renal Physiol. 293: F1501-F1511 [Abstract] [Full Text]  
• Fisher, J. W. (2003). Erythropoietin: Physiology and Pharmacology Update. Exp. Biol. Med. 228: 1-14 [Abstract] [Full Text]  
• Fisher, J. W., Brookins, J. (2001). Adenosine A2A and A2B receptor activation of erythropoietin production. Am. J. Physiol. Renal Physiol. 281: F826-F832 [Abstract] [Full Text]  
• KASISKE, B. L., VAZQUEZ, M. A., HARMON, W. E., BROWN, R. S., DANOVITCH, G. M., GASTON, R. S., ROTH, D., SCANDLING, J. D. JR., SINGER, G. G. (2000). Recommendations for the Outpatient Surveillance of Renal Transplant Recipients. J. Am. Soc. Nephrol. 11: S1-S86 [Abstract] [Full Text]  
• Boubenider, S., Vincent, I., Lambotte, O., Roy, S., Hiesse, C., Taburet, A.-M., Charpentier, B. (2000). Interaction between theophylline and tacrolimus in a renal transplant patient. Nephrol Dial Transplant 15: 1066-1068 [Full Text]  
• Cazzola, M., Guarnone, R., Cerani, P., Rovati, A., Ascari, E. (1998). Congenital Erythropoietin-Dependent Erythrocytosis Responsive to Theophylline Treatment. Blood 91: 360-362 [Full Text]  
• Cazzola, M., Mercuriali, F., Brugnara, C. (1997). Use of Recombinant Human Erythropoietin Outside the Setting of Uremia. Blood 89: 4248-4267 [Full Text]